open access

Vol 56, No 1 (2005)
Original papers
Published online: 2006-03-22
Submitted: 2013-02-15
Get Citation

Assessment of pro- and antyangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors

Marzena Korzeniewska, Krzysztof Kołomecki, Henryk Stępień, Maciej Naze, Tomasz Stępień, Krzysztof Kuzdak
Endokrynologia Polska 2005;56(1):39-82.

open access

Vol 56, No 1 (2005)
Original papers
Published online: 2006-03-22
Submitted: 2013-02-15

Abstract

Introduction: The growth and persistence of solid tumors and their metastases is connected with angiogenesis. This process is determined by activity of pro- and antyangiogenic factors. VEGF is the one of the most important factors having a stimulant effect on angiogenesis. Soluble forms of VEGF receptors are inhibitors of angiogenesis. The soluble forms of VEGF receptors containing extra cellular part of receptor, which binds ligand, seem to be real inhibitors of VEGF.
The aim of the study: Evaluation the value of serum VEGF and soluble forms of VEGF receptors concentration as a marker of malignancy in patients with hormonal inactive adrenal tumors.
Material and methods: Twenty seven patients (18 female, 9 male; mean age 48 ± 4.3 years) with adrenocortical carcinoma (N=8), adrenal metastases (N=4) and adrenocortical adenoma (N=15) were included in this study. Age- and gender-matched control samples were acquired from healthy volunteers (N=10). Serum VEGF and sVEGFR levels were determinated by means of ELISA assay. Statistical analysis was performed using the Student-t test, the Pearson’s test and the series test.
Results: In healthy controls mean VEGF level was 197.2 pg/ml, sVEGFR-1 43.5 pg/ml and sVEGFR-2 8976.3 pg/ml. Patients with adrenocortical carcinoma had the levels of VEGF (1263.8 pg/ml) significantly higher and of sVEGFR-2 (5893.7 pg/ml) significantly lower in comparison to control group (p0.05) but mean sVEGFR-1 (21.7 pg/ml) and sVEGFR-2 (7106.4 pg/ml) concentrations were significantly lower than in the control (p

Abstract

Introduction: The growth and persistence of solid tumors and their metastases is connected with angiogenesis. This process is determined by activity of pro- and antyangiogenic factors. VEGF is the one of the most important factors having a stimulant effect on angiogenesis. Soluble forms of VEGF receptors are inhibitors of angiogenesis. The soluble forms of VEGF receptors containing extra cellular part of receptor, which binds ligand, seem to be real inhibitors of VEGF.
The aim of the study: Evaluation the value of serum VEGF and soluble forms of VEGF receptors concentration as a marker of malignancy in patients with hormonal inactive adrenal tumors.
Material and methods: Twenty seven patients (18 female, 9 male; mean age 48 ± 4.3 years) with adrenocortical carcinoma (N=8), adrenal metastases (N=4) and adrenocortical adenoma (N=15) were included in this study. Age- and gender-matched control samples were acquired from healthy volunteers (N=10). Serum VEGF and sVEGFR levels were determinated by means of ELISA assay. Statistical analysis was performed using the Student-t test, the Pearson’s test and the series test.
Results: In healthy controls mean VEGF level was 197.2 pg/ml, sVEGFR-1 43.5 pg/ml and sVEGFR-2 8976.3 pg/ml. Patients with adrenocortical carcinoma had the levels of VEGF (1263.8 pg/ml) significantly higher and of sVEGFR-2 (5893.7 pg/ml) significantly lower in comparison to control group (p0.05) but mean sVEGFR-1 (21.7 pg/ml) and sVEGFR-2 (7106.4 pg/ml) concentrations were significantly lower than in the control (p
Get Citation

Keywords

angiogenesis; VEGF; sVEGFR-1; sVEGFR-2; adrenal tumors

About this article
Title

Assessment of pro- and antyangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors

Journal

Endokrynologia Polska

Issue

Vol 56, No 1 (2005)

Pages

39-82

Published online

2006-03-22

Bibliographic record

Endokrynologia Polska 2005;56(1):39-82.

Keywords

angiogenesis
VEGF
sVEGFR-1
sVEGFR-2
adrenal tumors

Authors

Marzena Korzeniewska
Krzysztof Kołomecki
Henryk Stępień
Maciej Naze
Tomasz Stępień
Krzysztof Kuzdak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl